Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US-Reference-Cited by-同舟云学术

Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US

Published:2022-06-30 Issue:6 Volume:5 Page:e2219535
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Ermer Theresa¹²³,Canavan Maureen E.¹⁴,Maduka Richard C.⁵,Li Andrew X.⁵,Salazar Michelle C.⁵,Kaminski Michael F.⁶,Pichert Matthew D.¹,Zhan Peter L.¹,Mase Vincent¹,Kluger Harriet⁷,Boffa Daniel J.¹

Affiliation:

1. Section of Thoracic Surgery, Department of Surgery, Yale School of Medicine, New Haven, Connecticut

2. Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, University of London, London, United Kingdom

3. Faculty of Medicine, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany

4. Cancer Outcomes Public Policy and Effectiveness Research Center, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut

5. Department of Surgery, Yale School of Medicine, New Haven, Connecticut

6. Yale School of Medicine, New Haven, Connecticut

7. Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2793792/ermer_2022_oi_220562_1655994248.20085.pdf

Reference64 articles.

1. Innovation in the pharmaceutical industry: New estimates of R&D costs

2. Availability of investigational medicines through the US Food and Drug Administration’s expanded access and compassionate use programs.;Puthumana;JAMA Netw Open,2018

3. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non–small-cell lung cancer.;Borghaei;J Clin Oncol,2021

4. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.;Motzer;Cancer,2020

5. Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation.;Unger;J Natl Cancer Inst,2019

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Socioeconomic and Demographic Disparities in Immunotherapy Utilization for Advanced Kidney and Bladder Cancer;Urologic Oncology: Seminars and Original Investigations;2024-11

2. Epidemiology and Screening for Melanoma;Hematology/Oncology Clinics of North America;2024-10

3. Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience;Urologic Oncology: Seminars and Original Investigations;2024-09

4. Disparities in PI3K/mTOR inhibitor use, toxicities, and outcomes among patients with metastatic breast cancer;Breast Cancer Research and Treatment;2024-05-04

5. Patterns of immunotherapy utilization for non-small cell lung cancer in Texas pre- and post-regulatory approval;Clinical and Translational Oncology;2024-03-30